Chime Biologics is a well-established Contract Development and Manufacturing Organization (CDMO) with a focus on providing cost-effective and customer-centric biopharmaceutical development and manufacturing solutions. Founded in 2013, the company supports clients through every phase of drug development, from initial analytical and process transfer to late-stage commercial manufacturing.
The company's operations are headquartered in China, serving a global market with premier-quality biopharmaceutical products. In the competitive landscape of Biopharma, Biotechnology, Health Care, Manufacturing, and Pharmaceutical industries, Chime Biologics distinguishes itself by offering comprehensive solutions for Global Supply.
Recently, Chime Biologics secured a Series A investment from Wuhan Optics Valley Financial Holding Group as of 01 December 2025, reflecting strong investor confidence in its capabilities and growth potential.